Compare Amgen, Inc. (AMGN) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Vanguard Short Term Corporate Bond ETF — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Vanguard Short Term Corporate Bond ETF trades at $78.7. The key difference: Amgen, Inc. pays a 2.77% dividend while Vanguard Short Term Corporate Bond ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | VCSH | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Fixed Income |
52-Week High | $388.16 | $80.20 |
52-Week Low | $271.18 | $78.61 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
VCSH trades at $78.61, down 0.1% with a bearish technical outlook showing 16 sell signals versus 1 buy. The ETF maintains consistent dividend distributions with recent payments of $0.29-$0.30 per share. News coverage highlights VCSH's competitive expense ratio and yield advantages over comparable short-term bond ETFs, though institutional positions show mixed adjustments.
The short-term corporate bond ETF faces headwinds from the Fed's indication of no rate cuts in 2026, potentially limiting near-term upside. Current technical weakness suggests cautious positioning, though the neutral oscillator reading and institutional interest from firms like BlueSky Wealth Advisors provide some support. The primary risk remains interest rate sensitivity in the current monetary policy environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
